Symbols

Symbols

PLX

PLX

Protalix BioTherapeutics Q3 2025 Earnings Call Highlights: Revenue Growth and Regulatory Challenges

Protalix BioTherapeutics Q3 revenue down 1% YoY to $17.9 mln.

Thursday Nov 06, 2025

Protalix BioTherapeutics to Announce Q3 2025 Results on November 13, 2025, Hosts Conference Call and Webcast

Protalix BioTherapeutics to report Q3 results, host conference call.

Wednesday Nov 05, 2025

Protalix Investigated for Securities Violations by Schall Law Firm.

Tuesday Nov 04, 2025

EMA Re-Examines Elfabrio Dosing Regimen, Protalix and Chiesi Seek Approval

Monday Nov 03, 2025

Chiesi, Protalix seek EU EMA re-examination of Elfabrio negative opinion.

Sunday Oct 19, 2025

Protalix BioTherapeutics: Overcoming Regulatory Hurdles to Unlock Rare Disease Market Potential

Friday Oct 17, 2025

Protalix BioTherapeutics Stock Plunges 29.83% as CHMP Rejects Elfabrio Dosing Schedule

Protalix, Chiesi Reaffirm Commitment to Fabry Disease Patients Despite EMA Panel Setback

Protalix Biopharmaceuticals Q3 2021 Earnings Presentation

Chiesi and Protalix BioTherapeutics receive negative CHMP opinion for Elfabrio dosing regimen.

Monday Sep 29, 2025

Protalix BioTherapeutics Sees Major Stake Increase Amid Goldman Sachs Expansion

Tuesday Sep 02, 2025

Protalix Biotherapeutics shares rise 5.81% intraday after CEO to present at H.C. Wainwright conference.

Protalix BioTherapeutics' CEO to present at H.C. Wainwright conference.

Monday Sep 01, 2025

Protalix BioTherapeutics Q2 Earnings Call: Robust Growth Amid Challenges

Friday Aug 22, 2025

Protalix Amends Market Offering Agreement with H.C. Wainwright for Equity Program

Tuesday Aug 19, 2025

Protalix's Sales Growth and Promising Pipeline Justify Buy Rating and $15 Price Target.

Saturday Aug 16, 2025

Protalix BioTherapeutics Experiences Strong Revenue Growth, Strategic Partnerships Drive Success

Friday Aug 15, 2025

Protalix BioTherapeutics Announces Q2 2025 Results, New CFO to Take Over.